Search - tctmd.com

Displaying 881 - 900 of 2440

Sort: Relevancy | Date

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Conference News EuroPCR 2018

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Michael O'Riordan

May 24, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

Podcast TCTMD Talking Points

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

Presentation

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

May 21, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

Presenter: Allen Jeremias

May 06, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Presenter: Rasha Al-Lamee

May 05, 2018

News Conference News SCAI 2018

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Shelley Wood

May 04, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

Podcast TCTMD Talking Points

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

May 02, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

Podcast Heart Sounds

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Todd Neale

April 24, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

Advertisement

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Alirocumab Price Slashed in Deal With Express Scripts

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Top Stories in Cardiology: April 2018

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content